Sino Medical Sciences Technology released its 2026 interim report on August 27, 2026. The company's total operating revenue was 305 million yuan, net profit attributable to the parent company was 50.3265 million yuan, and net cash inflow from operating activities was 94.1549 million yuan. The company's latest asset-liability ratio was 21.04 percent, up 1.20 percentage points from the previous quarter. Gross margin was 70.19 percent, return on equity was 5.05 percent, and diluted earnings per share was 0.12 yuan. The company had 24,300 shareholders. The top ten shareholders held 109 million shares, accounting for 26.18 percent of total share capital.
Sino Medical Sciences Technology InCompany reported 2026 interim net profit of 50.33 million yuan on 305 million yuan revenue with strong operating cash flow.
